As in the case of many chemotherapeutic drugs, also for ETO, the efficacy is often limited by the reduced bioavailability, the induction of several toxic effects that forces to limit dosage, the metabolism or environmental-induced inactivation, and the reduced selectivity towards cancer cells. The gene discussed is RUNX1T1; the disease is cancer.